Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05846789 · ClinicalTrials.gov registry record · Phase 2
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
A Phase 2 study of Metastatic Breast Cancer and Triple Negative Breast Cancer, sponsored by Kathy Miller.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 168
- Enrollment target
- 6
- Study locations
NCT05846789 is a Phase 2 study of Metastatic Breast Cancer and Triple Negative Breast Cancer that is actively recruiting participants, run by Kathy Miller. The registered enrollment target is 168 participants, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (18% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT05846789, a Phase 2 study of Metastatic Breast Cancer and Triple Negative Breast Cancer, is actively recruiting participants, sponsored by Kathy Miller.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 168 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a randomized Phase II study of standard of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab in in Black and non-Black patients with metastatic triple negative or ER low breast cancer.
Conditions Studied
Interventions
- DRUG Tocilizumab
- DRUG SOC Chemotherapy
Study Locations (6)
Indiana
- IU Health Joe and Shelly Schwarz Cancer Center - Carmel
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
- Sidney and Lois Eskenazi Hospital - Indianapolis
Georgia
- Emory University - Atlanta
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2024-07-02 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05846789
The ClinicalTrials.gov registry entry for NCT05846789 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (18% lower). The listed sponsor is Kathy Miller, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Tocilizumab is the first listed.
NCT05846789 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Indiana, Georgia, New York.
Frequently Asked Questions
What is clinical trial NCT05846789 about?
NCT05846789 is a clinical study titled "SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers". This is a randomized Phase II study of standard of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab in in Black and non-Black patients with metastatic triple negative or ER low breast cancer.
What is the current status of trial NCT05846789?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2024-07-02. Estimated completion is 2026-12.
What conditions does trial NCT05846789 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-low Breast Cancer.
What interventions are being tested in trial NCT05846789?
The interventions under investigation include: Tocilizumab (DRUG), SOC Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT05846789?
This trial is sponsored by Kathy Miller, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05846789 being conducted?
This trial has 6 study locations across Georgia, Indiana, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase 2
-
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.